The Port Delivery System continuously and reproducibly delivers ranibizumab over a period of at least 6 months, as shown in studies presented at the virtual Association for Research in Vision and Ophthalmology meeting.
“In vitro results support the fixed 24-week refill-exchange intervals in the Archway trial, where PDS Q24W showed to deliver vision and anatomic outcomes comparable to Q4W intravitreal ranibizumab injections,” Jay Stewart, MD, said.
The Port Delivery System (PDS, Genentech) contains a customized formulation of ranibizumab 100 mg/mL, a 10 times higher concentration